KR102410183B1 - 이소글리시리진산 또는 이의 염의 흡입용 제제, 및 호흡 기관 질환을 치료하기 위한 약물의 제조에서의 용도 - Google Patents

이소글리시리진산 또는 이의 염의 흡입용 제제, 및 호흡 기관 질환을 치료하기 위한 약물의 제조에서의 용도 Download PDF

Info

Publication number
KR102410183B1
KR102410183B1 KR1020187033045A KR20187033045A KR102410183B1 KR 102410183 B1 KR102410183 B1 KR 102410183B1 KR 1020187033045 A KR1020187033045 A KR 1020187033045A KR 20187033045 A KR20187033045 A KR 20187033045A KR 102410183 B1 KR102410183 B1 KR 102410183B1
Authority
KR
South Korea
Prior art keywords
inhalation
formulation
magnesium isoglycyrrhizinate
lactose
magnesium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187033045A
Other languages
English (en)
Korean (ko)
Other versions
KR20180132143A (ko
Inventor
홍메이 구
샨천 왕
시퀀 장
레이 후앙
홍지앙 쉬
웨이 송
핑 동
종잉 선
잉 장
데양 첸
Original Assignee
치아타이 티안큉 파마수티컬 그룹 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 치아타이 티안큉 파마수티컬 그룹 주식회사 filed Critical 치아타이 티안큉 파마수티컬 그룹 주식회사
Publication of KR20180132143A publication Critical patent/KR20180132143A/ko
Application granted granted Critical
Publication of KR102410183B1 publication Critical patent/KR102410183B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187033045A 2016-04-15 2017-04-14 이소글리시리진산 또는 이의 염의 흡입용 제제, 및 호흡 기관 질환을 치료하기 위한 약물의 제조에서의 용도 Active KR102410183B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610237175.3 2016-04-15
CN201610237175 2016-04-15
PCT/CN2017/080583 WO2017177966A1 (zh) 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其在制备治疗呼吸系统疾病药物中的应用

Publications (2)

Publication Number Publication Date
KR20180132143A KR20180132143A (ko) 2018-12-11
KR102410183B1 true KR102410183B1 (ko) 2022-06-17

Family

ID=60042326

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187033045A Active KR102410183B1 (ko) 2016-04-15 2017-04-14 이소글리시리진산 또는 이의 염의 흡입용 제제, 및 호흡 기관 질환을 치료하기 위한 약물의 제조에서의 용도

Country Status (13)

Country Link
US (2) US20190117568A1 (https=)
EP (1) EP3443954B1 (https=)
JP (2) JP7166929B2 (https=)
KR (1) KR102410183B1 (https=)
CN (2) CN109069442B (https=)
AU (1) AU2017251548B2 (https=)
BR (1) BR112018071208A2 (https=)
EA (1) EA201892350A1 (https=)
MX (1) MX394106B (https=)
MY (1) MY204600A (https=)
PH (1) PH12018502195A1 (https=)
SG (2) SG11201809042SA (https=)
WO (1) WO2017177966A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119345161A (zh) * 2024-12-25 2025-01-24 江苏长泰药业股份有限公司 一种丙酮酸钠雾化吸入制剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101190232A (zh) * 2006-11-30 2008-06-04 江苏正大天晴药业股份有限公司 一种注射用异甘草酸镁冻干粉针剂及其制备方法
CN103156930A (zh) * 2011-12-19 2013-06-19 张亚军 一种含芍药和甘草提取物的呼吸道给药制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891221A (en) * 1988-11-23 1990-01-02 Edward Shanborm Whole blood antiviral process and composition
WO2005004913A1 (ja) * 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
CN101023953B (zh) * 2006-07-24 2010-05-12 南开大学 治疗支气管哮喘的组合物
JP2008222682A (ja) * 2007-03-15 2008-09-25 Kumamoto Univ 線維化肺疾患治療薬、気道粘液分泌細胞過形成抑制剤および気道塞栓治療薬
CN101396368B (zh) * 2007-09-29 2010-12-01 江苏正大天晴药业股份有限公司 异甘草酸或其盐在制备治疗过敏性鼻炎药物中的应用
CN101669962A (zh) * 2009-09-18 2010-03-17 杭州市第六人民医院 复合甘草酸氨基酸注射液及其制备方法和应用
EP2608783B1 (en) * 2010-08-25 2018-09-19 Lurong Zhang Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
NZ628072A (en) 2012-03-13 2015-08-28 Respivert Ltd Crystalline pi3 kinase inhibitors
CN102920936A (zh) * 2012-09-17 2013-02-13 陈泉生 一种治疗呼吸道疾病的吸盐物及其制作方法
CN104042573A (zh) * 2014-06-03 2014-09-17 青岛市市立医院 一种异甘草酸镁冻干粉针剂及其制备方法
CN106237297A (zh) * 2016-08-30 2016-12-21 吉林紫鑫药业股份有限公司 一种用于治疗慢性支气管炎的药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101190232A (zh) * 2006-11-30 2008-06-04 江苏正大天晴药业股份有限公司 一种注射用异甘草酸镁冻干粉针剂及其制备方法
CN103156930A (zh) * 2011-12-19 2013-06-19 张亚军 一种含芍药和甘草提取物的呼吸道给药制剂

Also Published As

Publication number Publication date
JP2019511556A (ja) 2019-04-25
EP3443954A1 (en) 2019-02-20
MY204600A (en) 2024-09-05
EP3443954B1 (en) 2026-02-25
EA201892350A1 (ru) 2019-06-28
BR112018071208A2 (pt) 2019-02-12
US20190117568A1 (en) 2019-04-25
JP2021176903A (ja) 2021-11-11
EP3443954A4 (en) 2019-11-20
CN109069442A (zh) 2018-12-21
SG11201809042SA (en) 2018-11-29
MX2018012461A (es) 2019-09-18
PH12018502195A1 (en) 2019-09-23
JP7166929B2 (ja) 2022-11-08
KR20180132143A (ko) 2018-12-11
US20200368158A1 (en) 2020-11-26
CN111920785A (zh) 2020-11-13
AU2017251548B2 (en) 2022-02-17
WO2017177966A1 (zh) 2017-10-19
JP7309791B2 (ja) 2023-07-18
SG10202010192YA (en) 2020-11-27
CN111920785B (zh) 2022-05-20
AU2017251548A1 (en) 2018-11-15
MX394106B (es) 2025-03-24
US11534398B2 (en) 2022-12-27
CN109069442B (zh) 2020-09-04

Similar Documents

Publication Publication Date Title
US20090197941A1 (en) Pharmaceutical Compositons for the Treatment of Chronic Obstructive Pulmonary Disease
JPH09501700A (ja) 気道流路および肺疾患の処置のためのモメタゾンフロエートの使用
WO2021168173A1 (en) Methods and compositions for treating viral respiratory infections
CN112386595A (zh) 一种治疗呼吸系统病毒性感染的药物组合物
Yu et al. Pulmonary delivery of icariin-phospholipid complex prolongs lung retention and improves therapeutic efficacy in mice with acute lung injury/ARDS
WO2024109652A1 (zh) (-)-表没食子儿茶素没食子酸酯类化合物的应用
CA2435573A1 (en) Alkyl aryl polyether alcohol polymers for improvement of nasal breathing
JP7309791B2 (ja) イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用
CN101773468A (zh) 扎那米韦鼻用纳米混悬剂及其制备方法
JP2021176903A5 (https=)
Xie et al. Inhalation therapy for pulmonary fibrosis: chemical medicines and herbal medicines
US20240009227A1 (en) Use of a heparin composition in the treatment of viral lung diseases, acute and/or chronic lung diseases by soft mist inhaler or vibration mesh technology nebulizer through inhalation route
EA040563B1 (ru) Применение препарата для ингаляции на основе изоглицирризината магния для лечения заболеваний дыхательной системы
Zhang et al. Targeted Therapeutic Effect of Bavachinin Nanospheres on Pathological Site of Chronic Asthmatic Mice Model
HK1261173A1 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use of the inhaled preparation
HK1261173B (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use of the inhaled preparation
CN114796183A (zh) 益母草碱在制备用于预防或治疗呼吸系统疾病的药物中的应用
JPWO2017177966A5 (https=)
AU2020296829B2 (en) Method for treating asthma
CN120324446A (zh) 一种天然产物组合物对慢性阻塞性肺疾病的治疗作用
Han et al. Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis. Pharmaceutics 2023, 15, 1488
WO2026025266A1 (zh) 京尼平-1-β-D龙胆双糖苷在制备治疗慢性阻塞性肺疾病药物中的应用
JP2026502403A (ja) ゲニピン－１－β－Ｄゲンチオビオシドの調製薬物への使用
CN114848588A (zh) 一种福多司坦吸入用溶液制剂及其制备方法和用途
CN119258161A (zh) 一种提高呼吸道免疫力的中药组合物及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4